Nuclear Medicine

Nuclear medicine (also called molecular imaging) includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. Nuclear imaging is achieved by injecting small amounts of radioactive material (radiopharmaceuticals) into patients before or during their scan. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

cardiac amyloidosis on bone scan

ASNC reports shortage of cardiac amyloidosis radiotracers

The two vendors involved say supplies of PYP and HDP could be disrupted for months.

PET-CT imaging of 124-I evuzamitide and SPECT-CT imaging of 99mTc-p5+14 showed radiotracer uptake in both AL and ATTR amyloid throughout the myocardium. Emily B. Martin, Anne Kassira, Alan Stuckey, et al. A tale of two tracers - Amyloid imaging with investigational radiotracers iodine (124I) evuzamitide and 99mTc-p5+14 (AT-05). https://www.journalofnuclearcardiology.org/article/S1071-3581(25)00325-3/abstract.

Bayer expands into molecular imaging with cardiac amyloidosis tracer acquisitions

Bayer is acquiring two cardiac amyloidosis radiotracers from Attralus, one for PET and one for SPECT. The SPECT tracer is also a theranostic agent to both image and treat amyloidosis.

Bayer

Bayer expands into molecular imaging with 2 acquisitions

The company has reached a deal to purchase two investigational imaging agents from Attralus Inc., a Naples, Florida-based biopharmaceutical firm.

Sarah-Jane James, CT, MRI, molecular imaging senior market analyst for Signify Research, explains key trends in imaging systems she saw at the Radiological Society of North America (RSNA) 2025 meeting.

Key trends in medical imaging systems at RSNA 2025

Sarah-Jane James, imaging market analyst for Signify Research, discusses key trends in the specialty that she saw at the Radiological Society of North America's annual meeting. 

Thumbnail

Lantheus completes sale of SPECT business

Lantheus has signaled that the decision to sell its SPECT business will allow the company to focus more on growing its portfolio of PET radiodiagnostics and microbubbles. 

Positron NeuSight PET-CT 64 slice scanner

Positron raises $2M to expand PET-CT commercialization

The New York-based imaging company is now focused on expanding sales for the cost-effective PET-CT system it developed with Neusoft Medical Systems.

Novartis

Stanford Medicine’s Department of Radiology inks partnership with Novartis

They’ll work to accelerate research and development around targets for radioligand imaging across a wide range of oncological applications. 

Thumbnail

Leading nuclear medicine organizations collaborate to streamline PET accreditation

The groups have jointly endorsed a unified framework “to standardize and harmonize quantitative PET imaging worldwide.”